Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene

Thorax

Volumn 72, Issue 1, 2017, Pages 40-47

  Prickett, Michelle H ^a   Hauser, Alan R ^a   McColley, Susanna A ^a,b   Cullina, Joanne ^b   Potter, Eileen ^b   Powers, Cathy ^b   Jain, Manu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Bacterial Infection; Bronchiectasis; Cystic Fibrosis; Respiratory Infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; MESSENGER RNA; ANTIINFECTIVE AGENT; ANTIPORTER; BACTERIAL PROTEIN; MEXZ PROTEIN, PSEUDOMONAS AERUGINOSA;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CONVERGENT EVOLUTION; CYSTIC FIBROSIS; DNA SEQUENCE; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXY GENE; MEXZ GENE; PHENOTYPE; PREVALENCE; PROTEIN BINDING; PROTEIN DOMAIN; PSEUDOMONAS INFECTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SPIROMETRY; ADOLESCENT; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; INFANT; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; NEWBORN; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTIPORTERS; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENE EXPRESSION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RNA, MESSENGER; TIME FACTORS; YOUNG ADULT;

EID: 84977566041     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-208027     Document Type: Article

References (36)

1. Parad RB, Comeau AM. Newborn screening for cystic fibrosis. Pediatr Ann 2003;32:528-35.
2. Cystic Fibrosis Foundation. Patient registry: annual data report 2012. Bethesda, MD: Cystic Fibrosis Foundation, 2013.
3. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010;2:29ra31.
4. Cystic Fibrosis Foundation. Patient registry annual report 2014. Bethesda, MD: Cystic Fibrosis Foundation, 2014.
5. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8.
6. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;406:959-64.
7. Anwar H, Dasgupta M, Lam K, et al. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother 1989;24:647-55.
8. Lechtzin N, John M, Irizarry R, et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73:27-33.
9. Islam S, Oh H, Jalal S, et al. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect 2009;15:60-6.
10. Vogne C, Aires JR, Bailly C, et al. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48:1676-80.
11. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011;2:65.
12. Aires JR, Kohler T, Nikaido H, et al. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999;43:2624-8.
13. Yoneda K, Chikumi H, Murata T, et al. Measurement of Pseudomonas aeruginosa multidrug efflux pumps by quantitative real-time polymerase chain reaction. FEMS Microbiol Lett 2005;243:125-31.
14. Masuda N, Sakagawa E, Ohya S, et al. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:2242-6.
15. Vettoretti L, Plésiat P, Muller C, et al. Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2009;53:1987-97.
16. Westbrock-Wadman S, Sherman DR, Hickey MJ, et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999;43:2975-83.
17. Matsuo Y, Eda S, Gotoh N, et al. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. FEMS Microbiol Lett 2004;238:23-8.
18. Alguel Y, Lu D, Quade N, et al. Crystal structure of MexZ, a key repressor responsible for antibiotic resistance in Pseudomonas aeruginosa. J Struct Biol 2010;172:305-10.
19. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103:8487-92.
20. Feliziani S, Lujan AM, Moyano AJ, et al. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS ONE 2010;5:pii: e12669.
21. Marvig RL, Sommer LM, Molin S, et al. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 2015;47:57-64.
22. Jain M, Bar-Meir M, McColley S, et al. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. Transl Res 2008;152:257-64.
23. Mesaros N, Glupczynski Y, Avrain L, et al. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 2007;59:378-86.
24. Florindo C, Ferreira R, Borges V, et al. Selection of reference genes for real-time expression studies in Streptococcus agalactiae. J Microbiol Methods 2012;90:220-7.
25. Beinlich KL, Chuanchuen R, Schweizer HP. Contribution of multidrug efflux pumps to multiple antibiotic resistance in veterinary clinical isolates of Pseudomonas aeruginosa. FEMS Microbiol Lett 2001;198:129-34.
26. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4: 1073-81.
27. Jahandideh S. Diversity in structural consequences of MexZ mutations in Pseudomonas aeruginosa. Chem Biol Drug Des 2013;81:600-6.
28. Yang L, Jelsbak L, Marvig RL, et al. Evolutionary dynamics of bacteria in a human host environment. Proc Natl Acad Sci USA 2011;108:7481-6.
29. Caughlan RE, Sriram S, Daigle DM, et al. Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression. Antimicrob Agents Chemother 2009;53:5015-21.
30. Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8.
31. Hocquet D, Muller A, Blanc K, et al. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52: 1173-5.
32. Galli F, Battistoni A, Gambari R, et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012;1822:690-713.
33. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-7.
34. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000;55:205-9.
35. Wolter DJ, Black JA, Lister PD, et al. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. J Antimicrob Chemother 2009;64:294-300.
36. Recht MI, Douthwaite S, Dahlquist KD, et al. Effect of mutations in the A site of 16 S rRNA on aminoglycoside antibiotic-ribosome interaction. J Mol Biol 1999;286:33-43.